TACSTD2 and digestive system neoplasm: In a recent phase Ia clinical trial including gastric/GEJ adenocarcinoma and pancreatic cancers, CMG901 showed an ORR of 75% in patients with CLDN18.2 positive, pretreated gastric/GEJ adenocarcinoma.558 Another strategy is to apply ADCs that were developed and approved for other cancer entities, such as sacituzumab govitecan for Trop2-positive breast and urothelial cancers, in gastrointestinal tumors that share a high expression of the same target protein521,522.